CX Daily: China’s First Gene Therapy Struggles to Find Buyers Despite Price Cut

TOP STORIES

In Depth: China’s First Gene Therapy Struggles to Find Buyers Despite Price Cut

For much of the first half of 2026, Xiao Xiao, the 69-year-old co-founder and chairman of Belief BioMed Co. Ltd., was trying to sell a treatment his company had spent years developing. Xinjiuning is China’s first approved gene therapy for hemophilia, a rare condition that impairs the body’s ability to make blood clots.

FINANCE & ECONOMY

In Depth: China’s Offshore Trust Tax Grace Period Ends as Questions Linger